<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092165</url>
  </required_header>
  <id_info>
    <org_study_id>BLUE</org_study_id>
    <nct_id>NCT05092165</nct_id>
  </id_info>
  <brief_title>Methylene Blue for the Prevention of Hypotension During Hemodialysis</brief_title>
  <acronym>BLUE</acronym>
  <official_title>Methylene Blue for the Prevention of Hypotension During Hemodialysis: a Randomized Open Label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotension is a common complication of intermittent renal replacement therapy. Methylene&#xD;
      blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics&#xD;
      during renal replacement therapy in ambulatory patients, but evidence is lacking for&#xD;
      critically ill patients.&#xD;
&#xD;
      This trial will assess whether methylene blue can improve hemodynamics and blood pressure for&#xD;
      patients with shock requiring renal replacement therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint</measure>
    <time_frame>6 hours</time_frame>
    <description>Composite endpoint of: Increase in vasopressor dose in at least 15% of initial dose or interruption of dialysis or reduction in ultrafiltration rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>6 hours</time_frame>
    <description>Mean blood pressure below 65 mmHg for at least 5 minutes during renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum vasopressor dose</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum vasopressor dose, in micro-grams per kilogram per minute used during de first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in the intensive care unit</measure>
    <time_frame>60 days</time_frame>
    <description>Death in the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in the hospital</measure>
    <time_frame>60 days</time_frame>
    <description>Death during hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>Methylene Blue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylene blue will be infused during renal replacement therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy</description>
    <arm_group_label>Methylene Blue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Usual care during renal replacement therapy</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient or legal representative accepted trial enrollment&#xD;
&#xD;
          2. Age above 18 years&#xD;
&#xD;
          3. Chronic or acute kidney injury in need for renal replacement therapy&#xD;
&#xD;
          4. Blood pressure lower than 100 mmHg or in use of any vasopressor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Death considered imminent in the next 24 hours&#xD;
&#xD;
          3. Patients not on full code status&#xD;
&#xD;
          4. Hypertensive patients where dialysis was indicated to remove fluids&#xD;
&#xD;
          5. Known allergy to methylene blue&#xD;
&#xD;
          6. Known glucose-6-phosphate deficiency&#xD;
&#xD;
          7. Previously enrolled in the trial&#xD;
&#xD;
          8. Acute coronary Syndrome&#xD;
&#xD;
          9. Domiciliary nitrate use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Pontes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flavia R Machado, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Pontes, MD</last_name>
    <phone>+551155764848</phone>
    <email>pontes4@live.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Flavia R Machado, MD, PhD</last_name>
    <phone>+551155764848</phone>
    <phone_ext>17018</phone_ext>
    <email>frmachado@unifesp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04038002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Carla Pontes, MD</last_name>
      <email>pontes4@live.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Flavia Ribeiro Machado</investigator_full_name>
    <investigator_title>Chief of Critical Care Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon reasonable request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months after trial is published</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

